These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9438228)

  • 41. Reboxetine: tolerability and safety profile in patients with major depression.
    Tanum L
    Acta Psychiatr Scand Suppl; 2000; 402():37-40. PubMed ID: 10901157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.
    Humble M
    Acta Psychiatr Scand Suppl; 2000; 402():28-36. PubMed ID: 10901156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
    Bosc M; Dubini A; Polin V
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S57-70; discussion S71-3. PubMed ID: 9169311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Reboxetine (Edronax)].
    Souery D; Sternon J
    Rev Med Brux; 1999 Dec; 20(6):511-6. PubMed ID: 10672775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Noradrenaline in basic models of depression.
    Leonard BE
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S11-6; discussion S71-3. PubMed ID: 9169306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of reboxetine on depression in Parkinson's disease patients.
    Lemke MR
    J Clin Psychiatry; 2002 Apr; 63(4):300-4. PubMed ID: 12000202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is there a role for a pure noradrenergic drug in the treatment of depression?
    Montgomery SA
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. From symptoms to social functioning: differential effects of antidepressant therapy.
    Kasper S
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S27-31. PubMed ID: 10468326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of social functioning in depression.
    Bosc M
    Compr Psychiatry; 2000; 41(1):63-9. PubMed ID: 10646621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of antidepressants on psychomotor function with particular reference to reboxetine.
    Hindmarch I
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S17-21; discussion S71-3. PubMed ID: 9169307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoamine dysfunction and the pathophysiology and treatment of depression.
    Charney DS
    J Clin Psychiatry; 1998; 59 Suppl 14():11-4. PubMed ID: 9818625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reboxetine treatment of depression in Parkinson's disease.
    Lemke MR
    J Clin Psychiatry; 2000 Nov; 61(11):872. PubMed ID: 11105742
    [No Abstract]   [Full Text] [Related]  

  • 55. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.
    Brunello N; Mendlewicz J; Kasper S; Leonard B; Montgomery S; Nelson J; Paykel E; Versiani M; Racagni G
    Eur Neuropsychopharmacol; 2002 Oct; 12(5):461-75. PubMed ID: 12208564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel antidepressant strategies to optimize outcome.
    J Clin Psychiatry; 2000 Sep; 61(9):686-96. PubMed ID: 11030494
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of norepinephrine in the treatment of depression.
    J Clin Psychiatry; 1999 Sep; 60(9):623-31. PubMed ID: 10520985
    [No Abstract]   [Full Text] [Related]  

  • 58. Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition.
    Schreiber W; Krieg JC; Eichhorn T
    J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):550. PubMed ID: 10610387
    [No Abstract]   [Full Text] [Related]  

  • 59. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
    Healy D
    Acta Psychiatr Scand Suppl; 2000; 402():45-51. PubMed ID: 10901159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    Nelson JC; Portera L; Leon AC
    Biol Psychiatry; 2005 Jun; 57(12):1535-42. PubMed ID: 15953490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.